Q-omics provides the consensus-scored LYPLA2P2 profile across patient tissues and cancer cell-line models. LYPLA2P2 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, LYPLA2P2 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, LYPLA2P2 RNA expression shows 10,324 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, LUAD, and THYM as cancer lineages where LYPLA2P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LYPLA2P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LYPLA2P2 survival associations across molecular data types. LYPLA2P2 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LYPLA2P2 RNA expression–survival associations across cancer types. High LYPLA2P2 expression shows unfavorable associations in LIHC, LGG and LAML, but favorable associations in CESC, LUAD and UCEC. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify CESC as the clearest survival context for LYPLA2P2 RNA expression.
This table summarizes LYPLA2P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for LYPLA2P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LYPLA2P2 shows lower tumor expression in KICH and higher tumor expression in LUAD, COAD, LIHC, BRCA and LUSC. The LUAD box plot shows higher LYPLA2P2 RNA expression in tumor versus normal tissue (log2 FC = +0.198, t-test p < 0.001).
This table shows molecular features associated with LYPLA2P2 in patient tissues and cancer cell lines. In patient samples, LYPLA2P2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, LYPLA2P2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC.
